Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting

The Bausch & Lomb and Salix units are gaining sales momentum, execs said, while debt-reduction efforts remain ahead of schedule. They offered no excuses for a declining dermatology franchise, however.

Business teamwork puzzle pieces.

Valeant Pharmaceuticals International Inc. executives strived to accentuate the positive during a second quarter earnings call Aug. 8 and investors didn't completely reject the argument, as the troubled company's stock closed the trading day up nearly 2%. However, to buy into the good news, one must accept Valeant's assurances that it can turn around a struggling dermatology franchise and that ahead-of-schedule debt reduction efforts will enable it to regain overall footing before a heavy debt crunch in 2020-21.

CEO Joseph Papa characterized Valeant's path to recovery from a mountain of debt, legal troubles and patent expirations as one in which stabilization occurred last year and recovery is underway this year and next. (Also see "Debt-laden Valeant Sells Its Assets, More Divestments Likely" - Scrip, 10 January, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.